The Food and Drug Administration will hold a meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee on Nov. 21.
The purpose of the meeting is to discuss and make recommendations on a supplemental biologics license application from AstraZeneca AB for Andexxa, a drug used to reverse anticoagulation in patients with life-threatening bleeding, according to a Federal Register notice.
Public comments will be accepted until Nov. 20.
This story was produced by Bloomberg Law Automation.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.